drug protocol number

CKJX839A12

drug sponsor

Novartis

drug study

Inclisiran

drug trial site

Saud Al-Babtain Cardiac Center (Dammam) , King Salman Armed Forces Hospital(Tabuk) , King Fahd Armed Forces Hospital (Jeddah) , Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), International Medical Center (Jeddah)

drug status

Ongoing

drug phase